Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease.
Children
Chronic kidney disease
Hyperphosphatemia
Phosphate binder
Safety profile
Sucroferric oxyhydroxide
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
01
01
2020
accepted:
30
09
2020
revised:
08
09
2020
pubmed:
28
10
2020
medline:
10
2
2022
entrez:
27
10
2020
Statut:
ppublish
Résumé
Pediatric patients with advanced chronic kidney disease (CKD) are often prescribed oral phosphate binders (PBs) for the management of hyperphosphatemia. However, available PBs have limitations, including unfavorable tolerability and safety. This phase 3, multicenter, randomized, open-label study investigated safety and efficacy of sucroferric oxyhydroxide (SFOH) in pediatric and adolescent subjects with CKD and hyperphosphatemia. Subjects were randomized to SFOH or calcium acetate (CaAc) for a 10-week dose titration (stage 1), followed by a 24-week safety extension (stage 2). Primary efficacy endpoint was change in serum phosphorus from baseline to the end of stage 1 in the SFOH group. Safety endpoints included treatment-emergent adverse events (TEAEs). Eighty-five subjects (2-18 years) were randomized and treated (SFOH, n = 66; CaAc, n = 19). Serum phosphorus reduction from baseline to the end of stage 1 in the overall SFOH group (least squares [LS] mean ± standard error [SE]) was - 0.488 ± 0.186 mg/dL; p = 0.011 (post hoc analysis). Significant reductions in serum phosphorus were observed in subjects aged ≥ 12 to ≤ 18 years (LS mean ± SE - 0.460 ± 0.195 mg/dL; p = 0.024) and subjects with serum phosphorus above age-related normal ranges at baseline (LS mean ± SE - 0.942 ± 0.246 mg/dL; p = 0.005). Similar proportions of subjects reported ≥ 1 TEAE in the SFOH (75.8%) and CaAc (73.7%) groups. Withdrawal due to TEAEs was more common with CaAc (31.6%) than with SFOH (18.2%). SFOH effectively managed serum phosphorus in pediatric patients with a low pill burden and a safety profile consistent with that reported in adult patients.
Sections du résumé
BACKGROUND
Pediatric patients with advanced chronic kidney disease (CKD) are often prescribed oral phosphate binders (PBs) for the management of hyperphosphatemia. However, available PBs have limitations, including unfavorable tolerability and safety.
METHODS
This phase 3, multicenter, randomized, open-label study investigated safety and efficacy of sucroferric oxyhydroxide (SFOH) in pediatric and adolescent subjects with CKD and hyperphosphatemia. Subjects were randomized to SFOH or calcium acetate (CaAc) for a 10-week dose titration (stage 1), followed by a 24-week safety extension (stage 2). Primary efficacy endpoint was change in serum phosphorus from baseline to the end of stage 1 in the SFOH group. Safety endpoints included treatment-emergent adverse events (TEAEs).
RESULTS
Eighty-five subjects (2-18 years) were randomized and treated (SFOH, n = 66; CaAc, n = 19). Serum phosphorus reduction from baseline to the end of stage 1 in the overall SFOH group (least squares [LS] mean ± standard error [SE]) was - 0.488 ± 0.186 mg/dL; p = 0.011 (post hoc analysis). Significant reductions in serum phosphorus were observed in subjects aged ≥ 12 to ≤ 18 years (LS mean ± SE - 0.460 ± 0.195 mg/dL; p = 0.024) and subjects with serum phosphorus above age-related normal ranges at baseline (LS mean ± SE - 0.942 ± 0.246 mg/dL; p = 0.005). Similar proportions of subjects reported ≥ 1 TEAE in the SFOH (75.8%) and CaAc (73.7%) groups. Withdrawal due to TEAEs was more common with CaAc (31.6%) than with SFOH (18.2%).
CONCLUSIONS
SFOH effectively managed serum phosphorus in pediatric patients with a low pill burden and a safety profile consistent with that reported in adult patients.
Identifiants
pubmed: 33106892
doi: 10.1007/s00467-020-04805-y
pii: 10.1007/s00467-020-04805-y
pmc: PMC8009783
doi:
Substances chimiques
Drug Combinations
0
Ferric Compounds
0
sucroferric oxyhydroxide
0
Phosphorus
27YLU75U4W
Sucrose
57-50-1
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233-1244Références
Hruska KA, Mathew S, Lund R, Qiu P, Pratt R (2008) Hyperphosphatemia of chronic kidney disease. Kidney Int 74:148–157
doi: 10.1038/ki.2008.130
Kidney Disease: Improving Global Outcomes CKD-MBD Working Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl:S1–S130
Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617
doi: 10.1053/ajkd.1998.v31.pm9531176
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218
doi: 10.1097/01.ASN.0000133041.27682.A2
Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK (2001) Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131–2138
pubmed: 11562412
Hutchison AJ, Smith CP, Brenchley PE (2011) Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 7:578–589
doi: 10.1038/nrneph.2011.112
Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945–1953
doi: 10.1038/sj.ki.5000414
Kendrick J, Kestenbaum B, Chonchol M (2011) Phosphate and cardiovascular disease. Adv Chronic Kidney Dis 18:113–119
doi: 10.1053/j.ackd.2010.12.003
Hanudel MR, Salusky IB (2017) Treatment of pediatric chronic kidney disease-mineral and bone disorder. Curr Osteoporos Rep 15:198–206
doi: 10.1007/s11914-017-0365-0
Wingen AM, Fabian-Bach C, Schaefer F, Mehls O (1997) Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 349:1117–1123
doi: 10.1016/S0140-6736(96)09260-4
Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN (1986) Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 108:767–770
doi: 10.1016/S0022-3476(86)81064-2
Alon U, Davidai G, Bentur L, Berant M, Better OS (1986) Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab 12:320–325
pubmed: 3807830
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483
doi: 10.1056/NEJM200005183422003
Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M (2013) Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 83:959–966
doi: 10.1038/ki.2012.403
Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105
doi: 10.1161/01.CIR.0000020222.63035.C0
Renagel® (sevelamer hydrochloride). Highlights of prescribing information. Last accessed: 24 November 2019. Available from: http://products.sanofi.us/Renagel/Renagel.pdf
Renvela® (sevelamer carbonate) Highlights of prescribing information. Last accessed: 24 November 2019. Available from: http://products.sanofi.us/Renvela/Renvela.pdf
Haratake J, Yasunaga C, Ootani A, Shimajiri S, Matsuyama A, Hisaoka M (2015) Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol 39:767–771
doi: 10.1097/PAS.0000000000000385
Makino M, Kawaguchi K, Shimojo H, Nakamura H, Nagasawa M, Kodama R (2015) Extensive lanthanum deposition in the gastric mucosa: the first histopathological report. Pathol Int 65:33–37
doi: 10.1111/pin.12227
Zhang C, Wen J, Li Z, Fan J (2013) Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol 14:226
doi: 10.1186/1471-2369-14-226
Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Sucroferric Oxyhydroxide Study Group (2015) Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 30:1037–1046
doi: 10.1093/ndt/gfv006
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, PA21 Study Group (2014) A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86:638–647
doi: 10.1038/ki.2014.58
Wuthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA (2013) Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 8:280–289
doi: 10.2215/CJN.08230811
World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194
doi: 10.1001/jama.2013.281053
International Council for Harmonization (ICH) E6 Guideline for good clinical practice (GCP). Last accessed: 24 November 2019. Available from: https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637
doi: 10.1681/ASN.2008030287
Langman CB, Salusky IB, Greenbaum LA, Jueppner H, Leonard M, Nelson P, Portale A, Warady BA (2005) K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46(Supplement 1):S1–S121
VELPHORO (sucroferric oxyhydroxide). Summary of product characteristics Last accessed: 24 November 2019. Available at: https://www.ema.europa.eu/en/documents/product-information/velphoro-epar-product-information_en.pdf
Fathallah-Shaykh S, Drozdz D, Flynn J, Jenkins R, Wesseling-Perry K, Swartz SJ, Wong C, Accomando B, Cox GF, Warady BA (2018) Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease. Pediatr Nephrol 33:325–333
doi: 10.1007/s00467-017-3787-0
Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A (2010) Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 23:525–534
pubmed: 20119931
Covic A, Rastogi A (2013) Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol 14:153
doi: 10.1186/1471-2369-14-153